Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Abstract Immunotherapy has revolutionized cancer treatment; however, only 10–30% of patients experience durable survival benefits, while most malignancies remain resistant. In melanoma, vitiligo‐like depigmentation is a frequent and generally mild immune‐related adverse event, whose presence correla...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-11-01
Serija:	Advanced Science
Teme:	Fulvestrant immunotherapy vitiligo
Online dostop:	https://doi.org/10.1002/advs.202503979
Oznake:	Označite Brez oznak, prvi označite!